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Summary 
Unlike the highly polymorphic major histocompatibility complex (MHC) class Ia molecules, 
which present a wide variety of peptides to T ceils, it is generally assumed that the nonpolymorphic 
MHC class Ib molecules may have evolved to function as highly specialized receptors for the 
presentation of structurally unique peptides. However, a thorough biochemical analysis of one 
class Ib molecule,  the soluble isoform of Qa-2 antigen (H-2SQ7b),  has revealed that it binds 
a diverse array of structurally similar peptides derived from intracellular  proteins  in much the 
same manner as  the classical antigen-presenting molecules.  Specifically, we find  that  SQ7  b 
molecules are heterodimers of heavy and light chains complexed with nonameric peptides  in 
a 1:1:1 ratio. These peptides contain a conserved hydrophobic residue at the COOH terminus 
and a combination of one or more conserved residue(s) at P7 (histidine), P2 (glutamine/leucine), 
and/or P3 (leucine/asparagine) as anchors for binding SQ7  b. 2 of 18 sequenced peptides matched 
cytosollc proteins (cofilin and L19 ribosomal protein), suggesting an intraceUular source of the 
SQ7  b ligands.  Minimal estimates of the peptide repertoire  revealed that at least 200 different 
naturally processed self-peptides can bind SQ7  b molecules. Since Qa-2 molecules associate with 
a diverse array of peptides,  we suggest  that they function as effective presenting molecules of 
endogenously synthesized  proteins  like the class Ia molecules. 
T 
he MHC class I molecules serve as receptors for the trans- 
port and display of endogenously derived self- and non- 
sdf-peptides  at the cell surface. Non-sdf-peptides (e.g., de- 
rived from intracenular pathogens), when presented by class 
I molecules, form ligands for TCRs triggering antigen-specific 
lysis of the infected cells by CTL (reviewed in reference 1). 
The presentation  of self- and non-self-peptides is attributed 
to the ubiquitously expressed, highly diverse classical trans- 
plantation antigens known as the class Ia molecules, which 
in the mouse are encoded by the H-2K and D region genes. 
The diversity of the class Ia molecules mainly affects the an- 
tigen binding groove, which is thought to be important for 
presenting a wide variety of peptides  for immune surveil- 
lance by T cells (2). It is intriguing, however, that the majority 
of the class I genes in the mouse MHC (>30) distributed 
over the H-2Q, T, and M regions are not polymorphic. Their 
products, known as the nonclassical class Ib molecules, com- 
pared with the class Ia molecules are highly conserved, are 
expressed in a tissue specific manner, and their physiological 
role(s) is unknown (3, 4). 
Several recent studies have shown that H-2Q, T, and M 
molecules can serve as weak transplantation  antigens in vivo 
and in vitro (3-6). Further, they can also present intracel- 
lular pathogen-derived antigens to specific CTL (7-11). In 
several instances, the CTL responses are peptide dependent 
(7-9, 12-16), suggesting that one of the physiological func- 
tions of class Ib molecules might be to control immune re- 
sponses to intracellular pathogens akin to the class Ia mole- 
cules. Since, the antigen binding grooves  of the class Ib 
molecules are highly conserved, it is often thought that they 
may have evolved to present a limited set of unique peptides. 
This has been shown to be true for H-2M3 molecule, which 
requires an N-formylated peptide for binding, a feature present 
only in 13 mitochondrial (sdf)-proteins (7, 8, 12-16). Whether 
this is a general feature for class Ib binding peptides is not 
known. 
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molecules.  Encoded by two almost identical genes, Q7 and 
Q9 in the b haplotype mice, they are expressed on lymphoid 
cells and primitive hematopoietic progenitors in the bone 
marrow in adult mice (17). They are noncovalently  assodated 
with/3z-microglobulin (/32-m)  1 and exist in vivo in  two 
forms: the 40-kD Qa-2 antigen anchored to the membrane 
by glycophosphatidylinositol (GPI) (8,  19) and the 39-kD 
soluble molecule (20), SQa-2.  The switch from membrane- 
bound to soluble form is induced upon activation of the im- 
mune system and is thought to play a role in the regulation 
of the immune response (20,  20a). 
In an approach to solve the major puzzle as to the role 
of the numerous nonpolymorphic MHC class Ib molecules, 
we have analyzed the biochemical features of the soluble iso- 
form of Qa-2 antigen, SQ7  b. We find that SQ7  b molecules 
consist of heavy and light chains complezed with nonameric 
peptides in 1:1:1: ratio. These peptides contain a Q7b-specific 
binding motif  and are derived from intracdlular proteins. These 
data and the minimal estimates of SQ7  b binding peptide 
repertoire support the conclusion that Qa-2 molecules bind 
a diverse array of naturally processed  peptides in much the 
same manner as the highly polymorphic MHC class Ia mol- 
t'ales. 
Materials and Methods 
High Expression CeULine.  Large  quantities of SQa-2 complexes 
were produced in NS0 myeloma  cells  using pHEKmDHFR vector- 
based expression system (21). The eDNA encoding SQ7  b (20) was 
cloned into the SalI site of pHEKmDHFK downstream from the 
immunoglobulin heavy  chain enhancer and K  chain promoter splice 
site cassette (Fig. 1) to ensure efficient expression of the recom- 
binant eDNA. The eDNA differs  at two positions  from the reported 
sequence (22; and Coy'arts, E. C., and S. G. Nathenson, unpub- 
lished results); their location does not affect the peptide binding 
groove nor ~z-m interaction. Downstream from the eDNA is the 
3' end of the g constant region and its polyadenylation site. The 
vector also contains a DNA amplification selection marker, mu- 
tant dihydrofohte  reductase,  which binds methotrexate  (Mtx) poorly 
such that the transfected cells can be selected in concentrations of 
Mtx that would be normany lethal to the cells. Genes expressed 
in this manner in the pHEKmDHFR vector have been shown to 
be coamplified, resulting in high expression of the recombinant 
protein in myeloma cells (21). The recombinant pHEKmDHFK- 
sQ7b plasmid was introduced into NS0 cells by dectroporation. 
Mtx-resistant transfectants were selected  in DMEM supplemented 
with 5% FCS and 0.2/xM Mtx. The transfected pool was sub- 
jected to increasing concentrations of Mtx over a period of few 
months essenthlly as described  by Hendricks et al. (21). Cens resis- 
tant to 10/~M Mtx were cloned and SQ7  b high expressors were 
identified by F,  LISA. Selected  clones were then cultured with in- 
creasing concentrations of/vim. The highest SQ7  b secreting done 
resistant to 64 p2r  of Mtx was grown in a CdliGenTM-stirred  tank 
bioreactor (New Brunswick Sci., Edison, NJ) in 1:1 DMEM/RPMI 
supplemented with 3%  FCS, 1 mM sodium pyruvate, 0.01% 
pluronic I:.66, and 0.6/~M Mtx. Under these conditions, the cells 
1 Abbreviations used in this paper." ~z-m, ~Sz-microglobulin;  Mtx, metho- 
trexate; RP, reversed phase. 
grown with  agitation  of 40  rpm  produced up  to  10  mg of 
SQ7b/10 liters of tissue culture-spent medium over a period of 2-5 
d. The spent medium thus obtained was used for SQ7  b and pep- 
tide analysis. 
ELISA.  ELISA  was performed  by a modification  of  the method 
described by Harlow and Lane (23). Briefly,  polyginyl chloride 96- 
well phtes were coated with Qa-2-specific affanity-purifaed  mAb 
M46 (24). The uncoupled sites were blocked with 3% BSA diluted 
in PBS, pH 7.4. Tissue culture supernatants containing SQ7  b or 
purified SQ7  b in PBS were added to the wells and incubated over- 
night at 4~  Supernatants from the wells were aspirated and the 
wells were washed three  times with 0.5%  Tween-20 in  PBS 
(PBS/Tween). Biotinylated Qa-2-specitic mAb 20-8-4s (25) was 
added to the SQ7b-coated wells and incubated for 4 h at 4~  The 
plates were washed six times with PBS/Tween. The reaction was 
amplified  with ~-galactosidase-conjugated  strepta~din (Boehringer 
Mannheim Biochemicals, Indianapolis, IN) for 30 rain at 4~ 
washed six times as above, and devdoped using the ~-galactosidase 
substrate red-~-D-galactopyranoside  (Boehringer Mannheim Bio- 
chemicals). The concentration of SQ7  b in the superuatants was es- 
timated by recording  absorbance  of  the red product at 570 nm using 
a microtiter plate reader (Bio-Tck Instrs., Winooski, VT). 
Affinity  Chromatography.  SQ7  b molecules were purified from 
culture superuate ofNS0 transfectants.  The supernate  was first con- 
centrated to 1:10 the volume  by saturated  ammonium sulfate  precipi- 
tation (final concentration of 80%). The concentrate was quanti- 
tared using conformation-dependent mAb 20-8-4s and M46 in an 
ELISA (data not shown). The SQ7  b was affinity  purified using 3.2 
m120-8-4s-coupled protein A-Sepharose  column. Affanity  cohmns 
were prepared by coupling the protein A (Pharmacia  LKB,  Gaithers- 
burg, MD)-purified antibody to protein A-Sepharose  using dimethyl 
pimelimidate-2 HCI (Pierce, Rockford, IL) as described  by Harlow 
and Lane (23). The concentrate (120 ml) was passed over normal 
mouse serum, B22-249 (D  b specific; 26), and 20-8-4s columns, in 
that order, once at the rate of 0.5 ml/min. The B22-249 and 20-8- 
4s columns  were washed  with 20-column  volumes  of  PBS and duted 
with 5 ml of  0.1 N acetic acid (pH 2.9); the first 1 ml was discarded 
and the next 4.5 ml was collected. The ehted materials were dena- 
tured by increasing the concentration of acetic acid to 2.0 N (pH 
1.96) followed  by incubation of  the mixture in a boiling water bath 
for 5 rain. The mixture was cooled for 15 min at room tempera- 
ture. A 100-/~1 aliquot was used for amino acid analysis and an- 
other 100/~1 was subjected to amino acid sequence analysis. Data 
from both these analyses  were used to quantitate the initial amount 
of SQ7  b molecuhs. Peptides from 4.0 ml of the denatured mate- 
rial were separated  by centrifugation using a Centricon 3 filtration 
unit (Amicon Corp., Danvers, MA). The filtrate so obtained is the 
acid-cluted fraction. The acid-eluted fraction was concentrated to 
120/~1 in a speed-vac (Savant Instrs., Inc., Farmiagdale, NY), of 
which 10% was used to quantitate peptide yield by amino acid 
analysis. 
Reuersed-Phase (RP) HPLC.  The remainder of the acid-ehted 
ultrafiltrate (90%; ~2.7 nmol) was loaded onto a 1.0 x  250-ram 
nucleosil C18 column (Alhech Assoc. Inc., Deerfidd, IL) and sepa- 
rated by ILP-HPI,C  using HFI090 (Hewlett-Packard  Co., Palo  Alto, 
CA) equipped  with an on-line 1040 diode  array  detector. The column 
was eluted using 0.06% tn'fluoroacetic  acid, 5% acetonitrile,  water 
(buffer A) and 0.05% triiluoroacetic acid, 80% acetonitrih, water 
(buffer B). The gradient of the mobile phase consisted of 0% B 
at start (0.01 min), 37% B at 63 rain, 70% B at 95 min, 90% 
B at 105 min, and 100% B at 110 min, established at a rate of 
75/zl/min. Chromatographic data was acquired at 210 and 280 
nm. Eluting peaks were monitored at 210 nm and individual peaks 
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was quick frozen on dry ice and stored at  -70~  until further 
use. Repurification of individual peaks was performed essentially 
as above. The dution gradient consisted of either of two condi- 
tions: peaks 3, 5, 7, 10, and 19 were purified using 0% B at start 
(0.01 min), 37% B at 63 min, and 100% B at 70 min, at a flow 
rate of  50/zl/min; the remainder of  the peaks were repurified using 
20% B at 10 rain, 45% B at 70 min, and 100% B at 75 rain, at 
a  flow rate  of 50  /~l/min.  Peptide preparation from B22-249 
column-ehted material was separated  by RP-HPLC using the first 
gradient. The chromatogram so obtained was used to determine 
the specific peaks obtained from peptides eluted from SQ7  b. 
Amino Acid Analysis and Sequencing.  The peptide or protein 
preparations were acid hydrolyzed in 6 N HC1 in sacuo at 110~ 
for 24 h. The hydrolysate was speed-sac concentrated and made 
to 6/~1 in distilled water. A fraction (1 #1) was analyzed using HP 
AminoQuant (Hewlett-Packard  Co.) system  with o-phthahldehyde 
and f-moc precolumn derivatization. Fluorescence data was col- 
lected using an HP 1046 detector (Hewlett-Packard Co.). Quanti- 
ration of the affinity-purified  SQ7  b complex using the yields of al- 
anine (n  =  27.5), arginine (n  =  25.5), histidine (n  =  14), and 
leucine (n  =  31.5) from the amino acid analysis data resulted in 
5.75 nmol of the starting material from 120 ml of crude concen- 
trate. A similar analysis  of the acid-eluted ultrafxltrate  yielded 3.03 
nmol of peptides using the yields of histidine and leucine as the 
common insariant  residues in  the peptide after correcting for 
nonspecific  background. The background for this analysis  was de- 
termined as the amount of histidine and leucine present in the 
ultraffltrate of the material duted from B22-249 (isotype-matched 
nonspedfic mAb) column. 
Amino acid sequencing was performed by automated Edman 
degradation (AB1477A; Applied Biosystems,  Inc., Foster City, CA). 
The arginine residues in the heavy chain of SQ7  b were ascertained 
by sequence analysis  using a Porton 2000 sequencer  (Beckman  Instrs., 
Fullerton, CA). 
A data base search was performed to compare the peptide se- 
quences obtained with those stored in the Swiss Protein Data Bank 
(SwissProt release 25.0; 4/93) using the Wisconsin Genetics Com- 
puter Group (GCG) sequence analysis package (27). 
Results 
~~  ~$~-2 Mo~  in Mammal~n Gdk  Sin~ 
Qa-2 molecules are expressed in vivo as a heterogeneous mix- 
ture of  products of several related genes in relatively low quan- 
tities (28),  we have developed  a genetically engineered cell 
line producing high levels of a single Qa-2 product, SQ7  b. 
Full-size eDNA encoding SQ7  b (20) was subdoned into the 
pHEKmDHFR vector (21), introduced into NS0 cells by elec- 
troporation, and selected by stepwise methotrexate treatment 
(Fig. 1). NS0 cells (GPI- and SQa-2-negative BALB/c-derived 
myeloma) were used so that the host cell producing the recom- 
binant protein will be closely related to the cells expressing 
Qa-2 in vivo, which is important in the analysis of endoge- 
nous sdf-peptides. The highest SQa-2-secreting clones were 
estimated to produce "~0.5-1.0 mg of SQ7  b per liter of spent 
tissue culture medium when grown for 2-3 d in a bioreactor. 
The SQa-2 Peptide Binding Motif Is Unique.  The secreted 
form of Q7  b was purified from spent tissue culture medium. 
The spent medium containing SQ7  b was concentrated 10- 
fold by saturated ammonium sulfate precipitation. The in- 
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Figure  1.  High  expression vector containing SQ7  b eDNA used for 
~rexpmssion of  SQa-2 molecules  in a mammalian  my~loma  cell  line, NS0. 
The designations  in pHEKmDHFR  are from Hendricks et al. (21), and 
of SQa-2 are from Ulker et al. (20). 
tegrity of the SQ7  b molecules in the concentrate when tested 
by ELISA using a conformation-dependent mAb showed no 
loss of SQ7  b structure. SQ7  b molecules were further purified 
by  affinity chromatography using  20-8-4s  mAb  and  the 
resulting Qa-2 proteins were tested by SDS-PAGE (data not 
shown) and/or amino acid sequence analysis (see below). Pep- 
tides constitutively bound to SQ7  b were then purified from 
the affinity column eluate by acid denaturation followed by 
the separation of the low molecular weight peptides (acid- 
Table  1.  SQ7  b Binding Motif of Constitutively Bound Peptides 
Position of residue 
Pl  P2  P3  P4  P5  P6  P7  P8  P9 
Predominant residue*  H 
K*  Q  L  P 
A  L  N  E 
G  G 
K 
I  K  E  L 
V  L  Q  I 
Q  F  N  F 
E  M  K 
L  Y  S 
T  T 
Y  V 
* Predominant  residue  is defined  as the only  residue  that had a significant 
PTH amino acid yield at a given sequencing cycle. 
t  All  sequencing  cycles,  except  cycle  7, showed significant  signals  for  two 
or more PTH  amino acids,  and the residue  assignments for each cycle 
(position  in the peptide)  are listed  in the order of decreasing  yields  of 
the PTH  amino acid. 
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Figure 2.  RP-HPLC chromato- 
grams  of peptides  isolated from 
SQ7  b.  (A) Separation  of 90%  of 
the total peptide fraction  (Centricon 
3  filtrate)  isohted  from  affinity- 
purified SQ7  b molecules  by  acid 
denaturation followed by RP-HPLC 
(solid line). In the same experiment, 
peptides ehted from material puri- 
fied from B22-249 column was also 
chromatographed  (broken  line). 
Chromatography was performed as 
described in Materials and Methods. 
(B)  Chromatographs  of repurifi- 
cation of individual peaks indicated 
by  numbers  in  A  by  RP-HPI.C 
under  conditions  different  (see 
Materials  and Methods) from the 
above. Peaks 24, 26, and 30 did not 
yield a detectable peak on repurifi- 
cation (data not shown). Note that 
the seemingly single peaks in the 
first  chromatogram  separate  into 
two to three peaks. Peaks identified 
by numbers were subjected to au- 
tomated amino acid sequencing by 
Edman method. 
eluted peptide fraction) from the heavy and light chains by 
ultrafiltration. 
To determine whether Qa-2 molecules bind peptides and, 
if they do, to determine the binding motif, 5% of the total 
acid-eluted peptide pool obtained from ,,03.0 nmol of Qa-2 
molecules (before HPLC fractionation) was subjected to 15 
cycles of microsequence analysis. No significant phenylthio- 
hydantoin (PTH) amino acid signals were detectable beyond 
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tides associated  with SQ7  b are nonameric (Table  1).  Most 
strikingly, these peptides have a single residue,  histidine, at 
the seventh sequencing cycle (P7, position of the residue in 
the peptide) and a hydrophobic residue at the ninth cycle (Table 
1). Further, only two to three different amino acid residues 
were detected at Pl, P2, and P3, therefore, these positions 
also appear somewhat more conserved. In contrast, P4, P5, 
P6, and P8 are degenerate, i.e., a number of different struc- 
turally unrelated amino acids are represented at these posi- 
tions (Table 1). These data suggest that the SQ7  b molecules 
bind peptides and have a specific binding motif. 
Peptides Constitutively Bound to SQa-2 Are Derived  from In- 
tracellular Proteins.  Sequencing of the pool of peptides bound 
to MHC molecules provides only limited information, such 
as the binding motif and the overall  heterogeneity of the 
ligands. To gain further insight into the physico-ch~fical  prop- 
erties of the peptides bound to SQ7  b, such as the number 
of different peptides bound and sources of these peptides, we 
have purified peptides (,,o2.7 nmol of the acid-eluted frac- 
tion)  eluted from SQ7  b molecules by RP-HPLC  and se- 
quenced a number of individual peaks. Approximately 50 dis- 
tinct peaks were resolved by this method (Fig. 2 A, solid line) 
and 36 peaks were collected by hand. Due to the high back- 
ground in the first separation and to ensure purity of each 
peak, 16 of the 36 peaks (Fig. 2 A, arrows) were further sepa- 
rated individually  by RP-HPLC. In several instances, this pro- 
cedure resulted in further separation of the single peaks into 
two or three peaks  (Fig.  2 B). 
A total of 18 individual sequences were derived from auto- 
mated Edman sequencing of peaks indicated in Fig. 3 B be- 
cause several of the peaks contained more than one peptide 
(Table 2). A comparison of the individual peptide sequences 
with the pool peptide data (Table 1) shows general agree- 
ment between them (Table 3).  Almost all the individually 
sequenced peptides are nonameric (with the exception of pep- 
tide 10.1b [Table 2], which is a decamer). Further, the pep- 
tides predominantly use histidine at P7 (12/18 peptides) and 
a hydrophobic residue at the COOH terminus, either at P9 
or at Pl0 (predominantly leucine; Table 2). The remaining 
positions, including the somewhat conserved P2 and P3, are 
occupied most frequently by the same residues that were de- 
tected in the pool peptide sequence data (Table 2). In addi- 
tion, several amino acids that were not observed in the pool 
Table  2.  Amino Acid Sequence of Peptides Constitutively Bound to SQ7 b 
Position of residue 
Peptide 
peak ID  1  2  3  4  5  6  7  8  9  10  Protein source* 
7.1  a  K  Q  N  P  I  A  H  Q  L  -  Unknown 
b  A  L  A  E  L  P  H  E  I  -  Unknown 
10.1 a  K  Q  N  P  T  V  H  H  L  -  Unknown 
b  A  G  L  L  G*  M  R  S  G  Ls  Unknown 
18.1 a  K  L  I  K  V  Y  H  S  L  -  Unknown 
b  V  Q  N  X H  T  M  H  P  I  -  Unknown 
18.2  R  S  N  G  Q  V  H  M  L  -  Unknown 
19.1 a  K  L  T  G  I  K  H  E  L  -  Cofilin 
b  A  M  L  A  T  Y  H  K  L  -  Unknown 
c  G  Q  L  X  V  X  H  K  L  -  Unknown 
25.2 a  I  L  M  E  H  I  H  K  L  -  Ribmomal LI9 
b  A  Q  N  P  V  L  Y  Q  I  -  Unknown 
c  S  M  I  K  T  V  K  E  M  -  Unknown 
28.1  K  L  L  P  V  E  H  N  L  -  Unknown 
30.2 a  K  Q  L  I  V  T  Y  H  L  -  Unknown 
b  S  V  L  D  D  L  A  L  L  -  Unknown 
c  Y  E  S  P  L  M  X  F  L  -  Unknown 
36.1  D  L  L  G  T  L  H  N  L  -  Unknown 
* Protein source  was searched in the Swiss Protein  Data Bank (SwissProt release 24,0; 1/93) using the Wisconsin  Genetics Computer  Group (GCG) 
sequence analysis package (27). 
t Underline indicates probable presence of an alternate residue. 
s A 10th PTH amino acid was detected  for that peptide; leucine could  be the COOH-terminal residue  in 10.1b peptide since IX) is represented by 
glycine for that particular peptide. 
II X indicates that a PTH-amino acid could not be ascertained at that position. 
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Figure 3.  SQa-2 molecules exist as heterotrimers of heavy and light 
chains and peptides in approximately one stoichiometry. (,4) Combined 
yields of amino acids in the types I and II SQ7  b heavy  chains (filled bars) 
and flz-m (empty bars) showing equimolar amounts of heavy and light 
chains. Va112, LeuS, and Tyr7 are residues  of the type I heavy  chain; Va114, 
LeuT, and Tyr9 are residues of the type II heavy chain; Valg, IleT, and 
Tyrl0 are residues of flz-m uuxt for this calcuhtion. None of these residues 
are present in the peptide at the positions shown. (B) Combined yields 
(filled bars) of histidines at cycle  9 from the type I heavy chain and cycle 
11 from the type II heavy  chain compared with the histidine yield at cycle 
7 from the peptide (empty bars). 
peptide sequences were detected in the individual pepticle se- 
quences (Table 3). Most notable of these are arginine,  tyro- 
sine,  and alanine at P7,  and methionine  and glycine at P9 
(Tables 2 and 3). The higher degree of degeneracy observed 
at all positions in the individual peptide sequence data may 
be due to the differences in the sensitivity between the two 
approaches. 
A  homology search  against a protein data bank revealed 
2 of the 18 peptides, peptides 19.1a and 25.2a, had a 100% 
match with abundantly expressed murine intracellular pro- 
teins,  cofilin (an actin-binding protein;  29) and L19 (a 60S 
ribosomal protein;  30) (Table 2). Both peptides represented 
major peaks in the RP-HPLC profile (Fig.  2 A) and were 
recovered with high yidd (19.1a,  49.2 pmol;  25.2a,  110.7 
pmol). None of the peptides have homology to serum pro- 
teins. This suggests that  the SQa-2-associated peptides are 
derived from intracellular  proteins  of the host cell. 
Native SQ7 ~ Is a  Uniraolar Complex  of Heavy and Light 
Chains and Peptid~  To approach the question of the stoichi- 
ometry of the Qa-2 heavy chain,  light chain and peptides 
in  the complex,  we quantitated  the a/~nity-purified  SQ7  b 
molecules by sequence analysis.  Amino add sequencing of 
the first 20 residues of the complex revealed  that two types 
of heavy chains are present in almost equimolar amounts in 
the complex (not shown). One type (I) begins with a gly- 
cine residue at the NH2 terminus like almost all class I heavy 
chains (31), while the other type (II) has two additional amino 
acid residues (Argl and Ala2) at the NH2 terminus, which 
is consistent with the previously reported  data (32). 
We have used the yields of residues that occur in the two 
heavy chains of SQ7  b and flz-m to estimate the stoichiom- 
etry of the heavy and light  chains  in the class  I complex. 
The choices of the residues used as markers for this analysis 
were based on  the  following criteria.  (a)  When  identical 
residues were compared,  they occurred in the heavy chain 
and fl2-m at different  sequencing  cycles;  however,  to have 
comparable yidds, the residues had to occur at dose posi- 
Tablr  3.  Compilation of Different Amino Acid Residues that Occur at a Given Position in Individual Peptides and Comparison to Pool Peptide 
Sequences 
Position  in the peptide 
Pl  P2  P3  P4  P5  P6  P7  P8  P9  Pl0 
K*(6)*  Q  (6)  L  (7)  P  (5)  I  (2)  K  (1)  H  (12)  E  (3) 
A  (4)  L  (6)  n  (5)  E  (2)  V  (5)  L  (3)  R  (2)  Q (2) 
G  (1)  M (2)  I  (2)  G(3)  Q  (1)  F  (0)  Y  (2)  N(2) 
S  (2)  G  (1)  A (1)  K(2)  E  (0)  M  (3)  A  (1)  K (3) 
I  (1)  S  (1)  T  (1)  L  (1)  L  (2)  Y  (2)  S  (2) 
D  (1)  V  (1)  M(1)  A (1)  T  (5)  V  (3)  T  (0) 
R  (1)  E  (1)  S  (1)  I  (1)  Y  (0)  A  (1)  V  (0) 
V  (1)  D (1)  G  (1)  P  (1)  H (2) 
H  (1)  I  (1)  L  (1) 
Y  (1)  D  (1)  E  (1)  F  (1) 
T  (1)  M(1) 
P  (1) 
L  (13) 
I  (3) 
F  (0) 
G  (1) 
M  (1) 
L (1) 
" Bold letters indicate amino acid assignments from pool peptide sequences (see Table 1). 
Number of times a residue appears at a given position on compiling the individual peptide sequences (see Table 2) is given in parenthesis. 
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residues were compared, they occurred in the same sequencing 
cycle, and their relative yidds, in general, are known to be 
very similar, e.g., leucine and isoleucine. Thus, the combined 
yields of the two heavy chains using residues Va112, Leu5, 
and Tyr7 for type I and Vail4,  Lev7, and Tyr9 for type II 
heavy chains were compared to the yidds of residues Val9, 
Ile7, and Tyrl0 of/~2-m (Fig. 3 A). The data demonstrated 
that the heavy chains are associated with the tight chain (/32- 
m) in unimolar ratio (Fig.  3 A). Further, both the mouse 
and  bovine /32-m are  present  in  the  complex in  similar 
amounts as judged by the yields of their specific residues (data 
not shown). 
Amino acid sequence analysis was also used to quantitate 
the peptides bound to the SQ7  b molecules. For this quanti- 
tation, histidine was chosen as the marker residue because 
of the fact that it is the most common amino acid in the 
peptide at P7 (Table 2) and is not represented in the heavy 
or light chains at cycle 7. Histidine is present at cycle 9 in 
type I and at cycle 11 in type II SQ7  b heavy chains (32) but 
not in the peptide at these cycles (this report). This compar- 
ison revealed that PTHis represented ~65% of the yidd of 
histidines at cycles 9 and 11 of the two heavy chain sequences 
(Fig. 3 B). Since histidine at P7 occurred in 12 of 18 peptides 
sequenced, and if this distribution reflects the average occur- 
rence of this residue in the peptide" one would estimate pep- 
tide occupancy of "~97%. 
In another experiment designed to address this issue, we 
have directly determined the molar amounts of the purified 
SQ7  b molecules and  the  acid-duted peptide fraction.  To 
make this calculation, 2.5% of the starting amount of the 
affinity-purified heterotrimeric complex and 10% of the acid- 
duted peptide fraction were quantitated by amino acid anal- 
ysis. Using the yields of alanine, lencine" and arginine, it was 
determined that the affinity-purified starting material con- 
tained 5.75 nmol SQa-2 protein (see Materials and Methods). 
Similarly, using the yields of the conserved histidine and leu- 
dne residues in the peptides, it was determined that the acid- 
duted ultrafiltrate contained ~53% molar yield of peptides 
expected from 5.75 nmol of SQ7  b molecules (see Materials 
and Methods) if there were 1:1 peptide/MHC stoichiometry. 
This is in good agreement with the value of ,v65% obtained 
from the sequence analysis of the trimolecular complex. Both 
these values represent lower estimates because histidine is not 
the only residue present at P7 in all the peptides. In fact, 
as mentioned above, since histidine is represented only in 
'~65% of the individually sequenced peptides (Table 2), when 
corrected the actual value would be "~95%.  Together, the 
data are consistent with the conclusion that the majority of 
the SQa-2 molecules are occupied by peptides at least to the 
extent seen with yidds for HLA-B27-associated peptides (33). 
Thus, native SQ7  b molecules appear to be predominantly 
heterotrimers consisting of noncovalently associated heavy 
and light chains complexed with peptides in close to 1:1:1 
stoichiometry. 
Several Hundred Different Peptides Are Constitutively Bound 
to SQa-2 Molecules.  The properties of the peptides associated 
with SQ7  b suggest that they are very similar to those bound 
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to class Ia molecules. Since individual class Ia molecules can 
bind a large variety of peptides of different but related  se- 
quences, somewhere in the range of 200 to >1,000 (34), we 
addressed the question of the size of the peptide repertoire 
that could associate  with SQ7  b molecules. One estimate 
could be made by directly counting the number of peaks ob- 
tained from the two  RP-HPLC  chromatograms and  the 
number of peptide sequences obtained per peak. The number 
of peptide peaks from the first RP-HPLC separation is "~50 
(Fig. 2 A). Several  of these peaks on rechromatography  yielded 
an average of two peaks (Fig. 2 B), making the total number 
of resolvable peaks to be in the range of 100. Since, an av- 
erage of two peptide sequences were obtained per peak (Table 
2), it is reasonable to conclude that at least 200 diverse peprides 
can bind to SQ7  b molecules. This would be a minimum es- 
timate of the size of the peptide repertoire due to the semi- 
tivity of the analysis, which does not detect minor species 
ofpeptides that may be associated with the dass I molecules. 
The above estimate is consistent with another calculation 
based on molar yidds of the total peptides in the Centricon 
3 ultrafiltrate eluted from SQ7  ~ and the yields of individual 
peptides. If 3.03 nmol of the starting amount of peptides 
in the ultraf~trate contains 100 different peptides, then a single 
peptide that occupies 1.0% of SQ7  b should have a yield of 
30.3 pmol. Since the majority (15/18)  of the peptides se- 
quenced were represented in amounts <30.3 pmol (range: 
2.0-22.6 pmol, 0.07-0.7%; exceptions: peptide 19.1a, 1.6%; 
25.2a,  3.6%;  25.2b,  1.4%), we conclude that SQ7  b mole- 
cules can bind >100 different peptides. 
Discusslon 
The availability of SQa-2 molecules in large amounts pro- 
duced by genetically engineered mammalian cells allowed a 
thorough biochemical analysis of this molecule using senti- 
tire techniques. Our data demonstrate that SQ7  b, an MHC 
class Ib molecule, constitutively  binds several hundred different 
naturally processed peptides. In most respects, the properties 
of the bound peptides, such as the nonameric length, the 
presence of conserved residues at two positions, the intracd- 
lular source of the peptides, and the minimum estimated 
number of different peptides that can bind Qa-2 molecules, 
are similar  to MHC class Ia binding peptides. 
A  more refined  understanding of the properties of the 
SQ7  b binding peptides was achieved by examining the in- 
dividual peptide sequences than was possible from pool se- 
quence data. The most striking similarity between the data 
obtained from the pool sequence and that of individual pep- 
tides is the restricted usage of histidine at P7 and the pres- 
ence of a hydrophobic residue at the carboxy terminus (PC). 
Interestingly, but less frequently, arginine, tyrosine, and ala- 
nine were seen at P7.  These residues were not represented 
in the pool sequences probably because the relative molar abun- 
dance (,,020% when the yields of the three residues are com- 
bined) of these amino acids may have been bdow the threshold 
of detection under the conditions used for pool sequencing. 
In contrast to the conserved amino acid usage at Pl, P2, and 
P3 deduced from the peptide pool sequencing, these posi- tions show high sequence variability on analysis of individual 
sequences. Whereas Pl is genuinely structurally variable, P2 
and P3 show a propensity for either a hydrophobic or a polar 
residue. Thus, P2 and P3 are probably moderately conserved 
positions. The remainder of the positions (P4, P5, P6, and 
P8) in the pepti& are &generate. Thus, the data for individual 
peptide sequences point out that the mechanism for pepti& 
MHC interaction is complex and simply knowing the aUde 
specific-motif  is not sul~icient to predict the precise rules for 
pepti& binding. 
Based on the structural motif of the SQ7  b binding pep- 
tides, we suggest that the side chains of residues at P7 and 
PC (Pg/P10) probably serve as specificity anchors for binding 
to SQ7  b deft.  In addition to the dominant specificity an- 
chors, side chains of residues at P2 and P3 may play the role 
of accessory or alternate anchors that may be required for 
the specificity and/or affinity for binding to SQ7  b. It should 
be noted that at least one of the conserved amino add residues 
(P2, Gln or Leu; P3, Leu or Asn), or a structuraUy related 
residue, is used at P2 and/or P3 in the peptides that lack the 
dominant PTHis anchor (Table 2). Thus, in such peptides, 
P2 and/or P3 may play an important role in anchoring the 
peptide. On average, individual peptides contain only three 
of the four proposed anchors at P2, P3, PT, and P9. This 
is similar  to the number of anchors observed in HLA-A3 
binding peptides (35). A unique feature of the SQ7  b binding 
motif is the fact that, besides the COOH-terminal anchor 
(PC), the dominant anchor at P7 of the peptide is located 
distally towards the COOH-terminal end of the pepti&. This 
is in striking contrast with all the known aUde-specific dom- 
inant anchor positions of mouse (36-38) and human (33-35, 
39, 40) class Ia binding peptides and may be the consequence 
of the physico-chemical  architecture of the Qa-2 groove. 
Rotzschke et al. (41) have recently reported the sequence 
of peptide pool ehted from GPI-linked splenic and thymic 
Qa-2 complexes and proposed that "only a few different pep- 
tides are presented by these molecules" based on the assump- 
tion that each peptide uses four to five anchors for binding 
Qa-2. Furthermore, they suggested that Qa-2 functions as 
a restriction dement for peptides derived from gut-associated 
antigens.  Whereas the sequence data reported for the pep- 
tide pool presented here and by P,  otzschke et al. (41) are ex- 
tremely similar, the two studies differ drastically in the qualita- 
tive  and  quantitative  estimates  of Qa-2  binding peptide 
repertoire.  Using two approaches, we have determined em- 
pirically that a minimum of 200 different peptides can bind 
SQ7  b, a number similar to the minimum estimates of class 
Ia binding pepti& repertoire.  Several other observations also 
support our conclusion. First, our data from individual pep- 
tide sequences demonstrate that only a subset of Qa-2 binding 
anchors at P2, P3, P7, and Ix) is present in individual pep- 
tides. This, we suggest, enables the binding of a large array 
of diverse peptides to Qa-2. Second, the function of the Qa-2 
antigens in the immune response against gut-associated bac- 
teria is inconsistent with the known tissue distribution of 
these molecules (expressed only in lymphoid derived cells; 
reference 3). Our computer searches of data banks using an- 
chors at P7 and P9 together with auxiliary anchors at either 
P2 or P3 did not reveal homology to any particular group 
of proteins, pathogen derived or otherwise (Stroynowski, I., 
and B. Jameson, unpublished results).  Third, if the criteria 
used by Rotzschke et al. (41) to define Qa-2 binding motif 
in the peptides were indeed correct, then their computer 
searches should have found peptides derived from cofilin and 
L19 (reported here), both of which are mouse proteins (29, 
30) found in SwissProt, GenBank, and EMBL sequence data 
banks. Finally,  the ability to express SQa-2  and GPI-Qa-2 
in high amounts in a variety of transfected cells, including 
mydoma (this report), hepatomas, and L cells (18), and CHO 
cells ('~baczewski, P., and I. Stroynowski, unpublished  results). 
also argues against the contention that Qa-2 binding pep- 
tides are rare  or limiting. Thus,  Qa-2  molecules are not 
"receptors of higher stringency than ordinary class I mole- 
cules (41)" but they bind a large array of diverse peptides de- 
rived from endogenously synthesized and naturally processed 
proteins in much the same manner as the ordinary class I 
molecules. 
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